Posted on April 24, 2009 by Sitemaster
Dendreon has previously announced that the results of the IMPACT trial will be presented at the annual meeting of the American Urological Association at approximately 2:20 pm on Tuesday, April 28. The company has now announced that, in addition, it will hold a webcast conference call at 4:30 pm CT (5:30 pm ET, 2:30 pm PT) the same day to present these data to people unable to attend the AUA annual meeting. … READ MORE …
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipleucel-T | Comments Off on Provenge data results … for those who can’t get to the AUA meeting
Posted on April 21, 2009 by Sitemaster
Dendreon researchers have presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 trial suggesting that sipuleucel-T (Provenge) induces durable responses that can be maintained following an immune boost. These early data from the PROTECT trial were presented Sunday at the annual meeting of the American Association for Cancer Research in Denver. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: androgen-dependent, Provenge, sipleucel-T | Leave a comment »
Posted on November 21, 2008 by Sitemaster
Today’s reports cover such topics as:
- Diets high in fish and seafood and prostate cancer risk
- Testosterone therapy and prostate cancer risk
- A new, first-in-class drug enters prostate cancer trials
- The science behind products like Provenge … READ MORE …
Filed under: Diagnosis, Management, Prevention, Treatment | Tagged: diet, elesclomol, fish, Provenge, risk, seafood, sipleucel-T, testosterone | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 